More than half of patients who have cirrhosis of the liver also display neurocognitive impairments such as short term memory loss, a study led by a Loyola University Health System researcher has found.
Loyola neuropsychologist Christopher Randolph, PhD, and colleagues found that 54 percent of 301 cirrhosis patients who were tested scored below the 10th percentile for their age and education on a test that measures neurocognitive abilities.
"Neurocognitive impairment is a major issue in patients with liver disease," Randolph said. "This can affect patients' ability to do everyday tasks such as working, driving or managing their finances."
Randolph reported results May 3 during the Digestive Disease Week meeting of physicians and researchers in New Orleans. Randolph is a clinical professor in the Department of Neurology at Loyola University Chicago Stritch School of Medicine.
Neurocognitive impairment in liver patients is called hepatic encephalopathy. It is believed to be caused by toxins such as ammonia that diseased livers do not clear from the body. Randolph's study is the first to document how liver patients compare with the general population.
Liver patients from multiple centers nationwide were given a test developed by Randolph called the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS™). The widely used paper-and-pencil test takes 20 to 25 minutes and measures memory, attention, language and visual-spatial functions. It includes tasks such as identifying line drawings of common objects, repeating lists of digits, copying geometrical figures and recalling a story.
In the general population, the average score on RBANS tests is 100. Among liver patients in Randolph's study who had neurocognitive impairments, the average score was 74. This is lower than the average score of patients with early-stage Alzheimer's disease.
Prevalence of neurocognitive impairment was independent of age, gender, educational level or severity of the underlying disease.
The findings are a subset of a larger study to determine whether an experimental compound called AST-120 benefits liver patients who have neurocognitive impairments. AST-120 absorbs ammonia and other toxins. Patients have been randomly assigned to receive AST-120 or a placebo.
The study is funded by Ocera Therapeutics, which is developing compounds to treat liver diseases and other gastrointestinal disorders.
Jim Ritter | EurekAlert!
Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg
New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences